Evidence map›Paper›PMID 36959376›Full record

Observational studyBritish journal of cancer2023

The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study.

Lewis A Hall, Siobhan C McKay, James Halle-Smith, Joshua Soane, Daniel-Clement Osei-Bordom, Lesley Goodburn, Laura Magill, Thomas Pinkney, Ganesh Radhakrishna, Juan W Valle and 3 more

Full text readObservational Study
In one paragraph

Observational study in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Impact of Coronavirus Disease 2019 on the Diagnosis and Treatment of Pancreatic Cancer: An Observational Cohort Study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2024
    Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lewis A Hall *College of Medical and Dental Sciences, University of Birmingham, Birmingham, England. lxh753@bham.ac.uk.ORCID http://orcid.org/0000-0002-5012-2108
Siobhan C McKay *Queen Elizabeth Hospital, Birmingham, England.
James Halle-SmithQueen Elizabeth Hospital, Birmingham, England.
Joshua SoaneSouthend University Hospital, Southend-on-Sea, England.
Daniel-Clement Osei-BordomQueen Elizabeth Hospital, Birmingham, England.
Lesley Goodburn
Laura MagillBirmingham Surgical Trials Consortium, University of Birmingham, Birmingham, England.
Thomas PinkneyBirmingham Surgical Trials Consortium, University of Birmingham, Birmingham, England.
Ganesh RadhakrishnaThe Christie NHS Foundation Trust, Manchester, England.
Juan W ValleThe Christie NHS Foundation Trust, Manchester, England.ORCID http://orcid.org/0000-0002-1999-0863
Pippa CorrieCambridge University Hospitals NHS Foundation Trust, Cambridge, England.ORCID http://orcid.org/0000-0003-4875-7021
Keith J RobertsCollege of Medical and Dental Sciences, University of Birmingham, Birmingham, England.
CONTACT Study Group

Funding

Cancer Research UK 30195
6 · The paper itself

Abstract

introductionCONTACT is a national multidisciplinary study assessing the impact of the COVID-19 pandemic upon diagnostic and treatment pathways among patients with pancreatic ductal adenocarcinoma (PDAC).

methodsThe treatment of consecutive patients with newly diagnosed PDAC from a pre-COVID-19 pandemic cohort (07/01/2019-03/03/2019) were compared to a cohort diagnosed during the first wave of the UK pandemic ('COVID' cohort, 16/03/2020-10/05/2020), with 12-month follow-up.

resultsAmong 984 patients (pre-COVID: n = 483, COVID: n = 501), the COVID cohort was less likely to receive staging investigations other than CT scanning (29.5% vs. 37.2%, p = 0.010). Among patients treated with curative intent, there was a reduction in the proportion of patients recommended surgery (54.5% vs. 76.6%, p = 0.001) and increase in the proportion recommended upfront chemotherapy (45.5% vs. 23.4%, p = 0.002). Among patients on a non-curative pathway, fewer patients were recommended (47.4% vs. 57.3%, p = 0.004) or received palliative anti-cancer therapy (20.5% vs. 26.5%, p = 0.045). Ultimately, fewer patients in the COVID cohort underwent surgical resection (6.4% vs. 9.3%, p = 0.036), whilst more patients received no anti-cancer treatment (69.3% vs. 59.2% p = 0.009). Despite these differences, there was no difference in median overall survival between the COVID and pre-COVID cohorts, (3.5 (IQR 2.8-4.1) vs. 4.4 (IQR 3.6-5.2) months, p = 0.093).

conclusionPathways for patients with PDAC were significantly disrupted during the first wave of the COVID-19 pandemic, with fewer patients receiving standard treatments. However, no significant impact on survival was discerned.

Indexed as

Carcinoma, Pancreatic DuctalCOVID-19Pancreatic NeoplasmsCohort StudiesHumansPandemicsRetrospective StudiesUnited Kingdom

Identifiers

PMID36959376
PMCPMC10035482

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read268
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.